Successfully reported this slideshow.

The future of biosimilars market forecasts to 2015, opportunity analysis and regulatory pathways

514 views

Published on

Aarkstore.com announces, a new market research report is available in its vast collection
The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways
http://www.aarkstore.com/reports/The-Future-of-Biosimilars-Market-Forecasts-to-2015-Opportunity-Analysis-and-Regulatory-Pathways-107105.html
Summary:
The leading business intelligence provider, has released its latest research “The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways”. The report provides insights on the biosimilars market revenues and growth until 2015. Further, the distribution of revenues across key geographies such as the US, the top five countries in Europe and Japan are provided in the report. The report discusses the latest developments in the regulatory landscape and the evolving biosimilars approval pathways in Europe, the US and Japan. In-depth analysis into the individual segments of biosimilars market, their market forecasts and potential are also provided. The study analyzes the competitive landscape including benchmarking of the leading companies in the biosimilars market.
Scope
The scope of this report includes:
Analysis on the regulations for biosimilars market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan
Market forecasts and potential for the biosimilars market from 2008 to 2015. The key biologics classes included are human growth hormones, granulocyte colony stimulating factors, insulins, interferons and erythropoietins
Market characterization data for biosimilars including market size, market share and market potential
Key drivers and restraints that have a significant impact on the market
Competitive landscape of global biosimilars market including benchmarking of the leading companies. The key companies discussed in this report are Teva, Sandoz, Hospira Inc, STADA Arzneimittel AG, Ratiopharm, Dr.Reddy’s Laboratories and Biocon Ltd
Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global biosimilars market
Reasons to Buy
The report will enable business development and marketing executives strategizing their product launches to
Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the US, Europe and Japan
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps
Develop key strategic initiatives by studying the key strategies of top competitors
Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety
Table of Contents :
1 Drug Discovery In India and China – Executive Summary
1.1 Rising Financial and Regulatory Pressures on Western Pharma will Continue to Drive the Drug Discovery

  • Be the first to comment

  • Be the first to like this

The future of biosimilars market forecasts to 2015, opportunity analysis and regulatory pathways

  1. 1. Aarkstore.com announces, a new market research report is available in its vast collectionThe Future of Biosimilars - Market Forecasts to 2015,Opportunity Analysis and Regulatory Pathwayshttp://www.aarkstore.com/reports/The-Future-of-Biosimilars-Market-Forecasts-to-2015-Opportunity-Analysis-and-Regulatory-Pathways-107105.htmlSummary:The leading business intelligence provider, has released its latest research “TheFuture of Biosimilars - Market Forecasts to 2015, Opportunity Analysis andRegulatory Pathways”. The report provides insights on the biosimilars marketrevenues and growth until 2015. Further, the distribution of revenues across keygeographies such as the US, the top five countries in Europe and Japan areprovided in the report. The report discusses the latest developments in theregulatory landscape and the evolving biosimilars approval pathways in Europe, theUS and Japan. In-depth analysis into the individual segments of biosimilars market,their market forecasts and potential are also provided. The study analyzes thecompetitive landscape including benchmarking of the leading companies in thebiosimilars market.ScopeThe scope of this report includes:Analysis on the regulations for biosimilars market in the leading geographies of theworld – the US, the UK, Germany, France, Italy, Spain, and JapanMarket forecasts and potential for the biosimilars market from 2008 to 2015. Thekey biologics classes included are human growth hormones, granulocyte colonystimulating factors, insulins, interferons and erythropoietinsMarket characterization data for biosimilars including market size, market share andmarket potentialKey drivers and restraints that have a significant impact on the market
  2. 2. Competitive landscape of global biosimilars market including benchmarking of theleading companies. The key companies discussed in this report are Teva, Sandoz,Hospira Inc, STADA Arzneimittel AG, Ratiopharm, Dr.Reddy’s Laboratories andBiocon LtdKey M&A activities, licensing agreements, that have taken place between 2008 and2009 in the global biosimilars marketReasons to BuyThe report will enable business development and marketing executives strategizingtheir product launches toBuild effective strategies to launch pipeline products by identifying the latestregulatory developments in the US, Europe and JapanDevelop market-entry and market expansion strategies by identifying thegeographic markets poised for strong growthExploit in-licensing and out-licensing opportunities by identifying products thatcould fill their portfolio gapsDevelop key strategic initiatives by studying the key strategies of top competitorsReinforce R&D pipelines by identifying licensing strategies for acquiring newdelivery mechanisms that have more efficiency and better safetyTable of Contents :1 Drug Discovery In India and China – Executive Summary1.1 Rising Financial and Regulatory Pressures on Western Pharma will Continue toDrive the Drug Discovery Research Market Growth in India and China1.2 Inflammatory Diseases, Metabolic Disorders and Oncology are the Three MajorTherapeutic Areas of Drug Discovery Research in India and China1.3 Deals Landscape is Equally Driven by Mid-Size Pharma and Big Pharma withOncology and Metabolic Disorders as Key Therapy Area of Focus
  3. 3. 1.4 Funding Problems and Talent Shortage Will Be the Two Biggest Challenges inFuture for the Drug Discovery Players in India and ChinaFor More details Plz do contact :Aarkstore EnterprisePhone:08149852585Email: enquiry@aarkstore.comURL:www.aarkstore.comOur Website :www.aarkstore.comFacebook: http://www.facebook.com/aarkstoreLinkedin: http://in.linkedin.com/in/aarkstore

×